BVXV News and Press, BiondVax Pharmaceuticals Ltd. From 03/24/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips BiondVax (NASDAQ: BVXV ) stock is a big mover today, soaring on news of an antibody development agreement. As of this writing, BVXV stock has gained more than 26% as investors price in this catalyst. Source: Shutte...

Gainers: JX Luxventure Limited (LLL) +43%. Alpha Tau Medical (DRTS) +37%. Takung Art (TKAT) +31%. Emclaire Financial (EMCF) +32%. BiondVax (BVXV) +30%. Mercurity Fintech Holding (MFH) +26%. INmune Bio (INMB) +19%. Gracell (GRCL) +21%. Aptevo (APVO) +21%. Lilium (LILM) +20%. LiqTech Internatio...

Gainers: BiondVax Pharmaceuticals (BVXV) +39%. Alpha Tau Medical (DRTS) +38%. CollPlant Biotechnologies (CLGN) +10%. Aptevo Therapeutics (APVO) +8%. HOOKIPA Pharma (HOOK) +8%. Losers: Sonendo (SONX) -11%. Creative Medical Technology (CELZ) -9%. Lan...

Buying Penny Stocks Today? Here’s What You Need to Know If you’re looking to buy penny stocks right now, there are a few things to consider. For one, the stock market is more volatile than it has been in many months prior. This is the result of several larger factors impac...

Mercurity Fintech Holding (MFH) +65%. Fast Radius (FSRD) +21%. Nikola (NKLA) +18% after investor event. Femasys (FEMY) +13%. BiondVax Pharmaceuticals (BVXV) +13% on research pact to develop nanosized antibody therapies. Incannex Healthcare (IXHL) +12%. D-MARKET Elektronik&...

BiondVax Pharmaceuticals (NASDAQ:BVXV) is collaborating with the Max Planck Society, and the University Medical Center Göttingen in Germany for developing innovative nanosized antibodies (NanoAbs). Under the agreements, BiondVax will have an exclusive option for an exclusive worldwi...

BiondVax signs definitive collaboration agreement for the development of a pipeline of innovative nanosized antibody (NanoAb) therapies - Broad collaboration with Max Planck Institute for Multidisciplinary Sciences and University Medical Center Göttingen (UMG), Germany, for...

European Investment Bank Agrees in Principle to Extend the Maturity of its Loan until December 2027 with Additional Terms that Provide Continued Long-Term Support for BiondVax's New Strategy PR Newswire JERUSALEM , March 14, 2022 /PRNewswire/ -- BiondVa...

BiondVax to Present at Aegis Virtual Conference PR Newswire JERUSALEM , Feb. 22, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for th...

BiondVax to Present at BIO CEO & Investor Conference BiondVax to Present at BIO CEO & Investor Conference PR Newswire JERUSALEM , Feb. 15, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on de...